SLANG Worldwide Inc.

CNSX:SLNG Rapport sur les actions

Capitalisation boursière : CA$1.1m

SLANG Worldwide Résultats passés

Passé contrôle des critères 0/6

SLANG Worldwide has been growing earnings at an average annual rate of 30%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been growing at an average rate of 11.7% per year.

Informations clés

30.0%

Taux de croissance des bénéfices

50.2%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie23.1%
Taux de croissance des recettes11.7%
Rendement des fonds propresn/a
Marge nette-102.2%
Dernière mise à jour des bénéfices30 Jun 2024

Mises à jour récentes des performances passées

Recent updates

Health Check: How Prudently Does SLANG Worldwide (CSE:SLNG) Use Debt?

Dec 26
Health Check: How Prudently Does SLANG Worldwide (CSE:SLNG) Use Debt?

Is SLANG Worldwide (CSE:SLNG) A Risky Investment?

Sep 09
Is SLANG Worldwide (CSE:SLNG) A Risky Investment?

Is SLANG Worldwide (CSE:SLNG) A Risky Investment?

May 26
Is SLANG Worldwide (CSE:SLNG) A Risky Investment?

Health Check: How Prudently Does SLANG Worldwide (CSE:SLNG) Use Debt?

Mar 28
Health Check: How Prudently Does SLANG Worldwide (CSE:SLNG) Use Debt?

Is SLANG Worldwide (CSE:SLNG) Using Too Much Debt?

Dec 11
Is SLANG Worldwide (CSE:SLNG) Using Too Much Debt?

The SLANG Worldwide (CSE:SLNG) Share Price Is Up 92% And Shareholders Are Holding On

Mar 02
The SLANG Worldwide (CSE:SLNG) Share Price Is Up 92% And Shareholders Are Holding On

Ventilation des recettes et des dépenses

Comment SLANG Worldwide gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

CNSX:SLNG Recettes, dépenses et bénéfices (CAD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 2429-30210
31 Mar 2432-23220
31 Dec 2335-19220
30 Sep 2340-27230
30 Jun 2339-29240
31 Mar 2340-28250
31 Dec 2238-29260
30 Sep 2235-47280
30 Jun 2236-48300
31 Mar 2237-48310
31 Dec 2137-51330
30 Sep 2136-52290
30 Jun 2134-52250
31 Mar 2126-45270
31 Dec 2022-14270
30 Sep 2021-187490
30 Jun 2023-178530
31 Mar 2027-162520
31 Dec 1926-200510
30 Sep 19229280
30 Jun 1915-10310
31 Mar 198-42260
31 Dec 185-28200
30 Sep 183-31150
31 Dec 170-100

Des revenus de qualité: SLNG is currently unprofitable.

Augmentation de la marge bénéficiaire: SLNG is currently unprofitable.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: SLNG is unprofitable, but has reduced losses over the past 5 years at a rate of 30% per year.

Accélération de la croissance: Unable to compare SLNG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Bénéfices par rapport au secteur d'activité: SLNG is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).


Rendement des fonds propres

ROE élevé: SLNG's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé